PureTech Health (PRTC) Debt Ratio (2020 - 2022)

PureTech Health (PRTC) reported Debt Ratio of 0.01 for Q4 2022, down 54.08% year-over-year from 0.02 in Q4 2021, and down 54.08% on a QoQ basis from 0.02 in Q4 2021.

PureTech Health (PRTC) has 3 years of Debt Ratio data on file, last reported at 0.01 in Q4 2022.

  • Quarterly Debt Ratio fell 54.08% year-over-year to 0.01 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 0.01 (down 54.08% YoY) and the FY2022 annual result came in at 0.01, down 54.08% from the prior year.
  • Debt Ratio declined to 0.01 in Q4 2022 per PRTC's latest filing, from 0.02 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.02 in Q4 2021 and bottomed at 0.01 in Q4 2022.
  • The 3-year median for Debt Ratio is 0.01 (2020), against an average of 0.01.
  • The widest annual swing landed in 2021, when Debt Ratio climbed 6.77%; it then tumbled 54.08% in 2022.
  • Tracing PRTC's Debt Ratio over 3 years: stood at 0.01 in 2020, then advanced by 6.77% to 0.02 in 2021, then plunged by 54.08% to 0.01 in 2022.
  • Per Business Quant, the three latest PRTC Debt Ratio figures stand at 0.01 (Q4 2022), 0.02 (Q4 2021), and 0.01 (Q4 2020).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn 0.18
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - 1.41
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 0.05
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -
10 PureTech Health 86.36 Mn -190.94 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 0.01
Dec 31, 2021 0.02
Dec 31, 2020 0.01